Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

21.03 -0.28 (-1.33%)
Streaming Delayed Price Updated: 3:30 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
News headline image
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Wednesday ↗
UBS cut the price target for Adobe Inc. (NASDAQ: ADBE) from $635 to $575. Adobe shares fell 2.3% to $541.06 in pre-market trading. SVB Leerink lowered the price target on... 
Via Benzinga
News headline image
Expert Ratings For Sarepta Therapeutics ↗
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed th... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 5, 2021 ↗
Upgrades For IGM Biosciences Inc (NASDAQ: 
Via Benzinga
News headline image
Analyst Ratings For Sarepta Therapeutics ↗
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021 ↗
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
News headline image
Why Sarepta Therapeutics Shares Dropped More Than 16% This Week ↗
The biotech stock fell a little more than $72 since its close last Friday. 
Via The Motley Fool
News headline image
Expert Ratings For Sarepta Therapeutics ↗
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ: 
Via Benzinga
News headline image
Sarepta Therapeutics (SRPT) Q3 2021 Earnings Call Transcript ↗
SRPT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
News headline image
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
News headline image
Is This Beaten Down Biotech a Bad News Buy? ↗
It has lagged the market over the last five years but with a promising gene therapy, is Sarepta worth another look? 
Via The Motley Fool
News headline image
Earnings Scheduled For November 3, 2021 ↗
Companies Reporting Before The Bell • R.R.Donnelley & Sons (NYSE:RRD) is likely to report quarterly earnings at $0.32 per share on revenue of $1.19 billion.... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
News headline image
Why Sarepta Therapeutics Fell 14.7% This Week ↗
Investors were unimpressed by the company's clinical and financial news. 
Via The Motley Fool
News headline image
50 Biggest Movers From Yesterday ↗
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
Via Benzinga
News headline image
Why Sarepta Therapeutics Tumbled Today ↗
Investors weren't wowed by a company update, or by news of a fresh stock issue. 
Via The Motley Fool
News headline image
40 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Revance Therapeutics (NASDAQ:RVNC) stock moved upwards by 17.79% to $24.09 during Wednesday's pre-market session. The company's market cap stands at $1.7... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
News headline image
A Peek Into The Markets: US Stock Futures Gain Ahead Of CPI, Fed Minutes ↗
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the Dow Jones dropped more than 100 points in the previous session. Investors are... 
Via Benzinga
Topics Economy Stocks
News headline image
5 Stocks To Watch For October 13, 2021 ↗
Some of the stocks that may grab investor focus today are: Wall Street expects JPMorgan Chase & Co. (NYSE: JPM) to report quarterly earnings at $3.00 per share on revenue... 
Via Benzinga
News headline image
What 5 Analyst Ratings Have To Say About Sarepta Therapeutics ↗
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:... 
Via Benzinga
News headline image
Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements ↗
Sarepta Therapeutics Inc (NASDAQ: SRPT) shared new analyses and functional data from its SRP-9001 development program and the details of Study SRP-9001-301 (EMBARK... 
Via Benzinga
News headline image
Sarepta, Codiak Nix Exosome Therapy Development Pact ↗
Sarepta Therapeutics Inc (NASDAQ: SRPT) notified Codiak BioSciences Inc (NASDAQ: CDAK) that it would terminate the two-year Research License and Option... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight ↗
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2021 ↗
Upgrades For Alcoa Corp (NYSE: 
Via Benzinga
News headline image
5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal ↗
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector. 
Via Talk Markets
News headline image
The Latest Barron's Picks And Pans Include General Electric, Netflix, Reddit And More ↗
This weekend's Barron's reveals what market strategists recommend for a stock market that likely will struggle this fall. Other featured articles discuss biotech stocks... 
Via Benzinga
News headline image
'Fast Money Halftime Report' Picks For August 24 ↗
On CNBC's "Fast Money Halftime Report," Stephanie Link said Aptiv PLC (NYSE: APTV) is worthy of a buy. Jon Najarian bought Sarepta Therapeutics Inc (NASDAQ: SRPT) on... 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.